Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· March 3, 2026

James River (JRVR) Earnings Call Transcript

View original at finance.yahoo.com
James River (JRVR) Earnings Call Transcript Image source: The Motley Fool. DATE Tuesday, March 3, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Frank D’Orazio Chief Financial Officer — Sarah Doran Operator Need a quote from a Motley Fool analyst?…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • New money yields remain in the 5% range, well above current book yield of 4.5%

    80% confidence
  • Future success will be driven by combination of refined risk appetite, operational efficiencies from cost savings, and technology platform deployment

    80% confidence
  • North American E&S market is vast with attractive opportunities in 2026, particularly for smaller insureds

    80% confidence
  • Company observing declining frequency trends for recent accident years in E&S segment

    80% confidence
  • Submission flow across casualty-focused business remains healthy with 4% overall growth for 2025

    80% confidence
  • Active portfolio management actions are largely behind us, with meaningful opportunities for profitable top line growth in 2026

    80% confidence
  • Company is targeting smaller accounts with higher renewal retention ratios that have proven more profitable over 20+ year history

    80% confidence
  • Company sees opportunity to scale small business unit and specialty divisions like Allied Health and Professional Liability

    80% confidence
  • Technology adoption will be a tangible differentiator in optimizing SME platform and wholesale-only distribution model

    80% confidence
  • Company created nearly $13 million in expense savings and reduced G&A expenses by about 9% overall in 2025

    80% confidence
  • AI underwriting tools will enhance underwriting judgment, not replace it, helping assess risk more consistently and identify outliers earlier

    80% confidence
  • Rate change remained positive at 9% for the year, consistent with 2024 and above loss trend

    80% confidence
  • Expected performance for 2026 to generate low- to mid-teens return on average tangible common equity

    80% confidence
  • On a go-forward basis, effective tax rate expected to be in line with U.S. statutory rate

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com